{"gene":"ELAC2","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":2011,"finding":"ELAC2 functions as tRNase Z in human mitochondria, responsible for 3' end processing of mitochondrial tRNAs. Silencing ELAC2 by siRNA resulted in impaired 3' end processing of multiple mt-tRNAs (tRNA-Val, tRNA-Lys, tRNA-Arg, tRNA-Gly, tRNA-Leu(UUR), tRNA-Glu) encoded on both mtDNA strands, establishing its role as the mitochondrial 3'-end endonuclease.","method":"siRNA knockdown, RT-PCR, northern blot analysis","journal":"RNA biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean knockdown with defined molecular phenotype (tRNA processing intermediates), replicated across multiple mt-tRNA substrates, corroborated by independent studies","pmids":["21593607"],"is_preprint":false},{"year":2011,"finding":"ELAC2 exhibits dual nuclear/mitochondrial localization. Alternative translation initiation from the second AUG of ELAC2 mRNA (due to unfavorable context of the first AUG) produces a protein lacking the mitochondrial targeting sequence, which is routed to the nucleus instead. The full-length protein (translation from the first AUG) localizes to mitochondria.","method":"GFP fusion protein expression, fluorescence microscopy, immunofluorescence, alternative start codon mutagenesis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct localization by GFP fusion imaging combined with mechanistic explanation via alternative translation initiation mutagenesis; corroborated by immunofluorescence in a separate study (PMID:21593607)","pmids":["21559454","21593607"],"is_preprint":false},{"year":2013,"finding":"Mutations in ELAC2 cause accumulation of mitochondrial RNA precursors (unprocessed mt-tRNA 3' ends) and impaired mitochondrial translation, leading to infantile hypertrophic cardiomyopathy and complex I deficiency. Complementation of mutant cell lines with wild-type ELAC2 restored RNA processing, establishing causality.","method":"Patient cell/tissue RNA analysis, complementation experiments in mutant cell lines, yeast model","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — complementation rescue experiment directly linking ELAC2 loss-of-function to mt-RNA processing defect, replicated in muscle, fibroblasts, and yeast model","pmids":["23849775"],"is_preprint":false},{"year":2003,"finding":"ELAC2 physically interacts with the gamma-tubulin complex. Overexpression of ELAC2 in tumor cells causes a delay in G2-M progression with accumulation of cyclin B levels.","method":"Biochemical pulldown/co-immunoprecipitation, cell cycle analysis (cyclin B accumulation)","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 3 / Weak — single lab, interaction reported by biochemical analysis without reciprocal Co-IP or structural validation; functional link to G2-M delay observed but mechanism not fully resolved","pmids":["12569551"],"is_preprint":false},{"year":2006,"finding":"ELAC2 associates with activated Smad2 via an interaction between the C-terminal MH2 domain of Smad2 and the N-terminal region of ELAC2. ELAC2 also associates with the nuclear Smad2 partner FAST-1 and potentiates the interaction of activated Smad2 with transcription factor Sp1. siRNA-mediated knockdown of ELAC2 suppresses TGF-beta-induced growth arrest in prostate cells, and ELAC2 potentiates activation of the p21 CDK inhibitor promoter by TGF-beta.","method":"Co-immunoprecipitation, domain mapping, siRNA knockdown, luciferase reporter assay, growth arrest assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal domain-mapping Co-IP plus functional siRNA knockdown with defined growth arrest phenotype and reporter assay; single lab","pmids":["16636667"],"is_preprint":false},{"year":2005,"finding":"The yeast ELAC2 homolog TRZ1 is involved in RNA processing in vivo. A trz1 deletion mutant's temperature sensitivity is rescued by multiple copies of REX2 (encoding an RNA 3' processing protein). The conserved histidine motif and C-terminal P-loop nucleotide-binding motif of Trz1p are essential for function, as mutations in these motifs abolish complementation.","method":"Yeast genetic suppression screen, plasmid-based complementation, site-directed mutagenesis","journal":"BMC molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (suppression by REX2) plus active-site mutagenesis demonstrating catalytic residue requirements; yeast model, single lab","pmids":["15892892"],"is_preprint":false},{"year":2005,"finding":"Recombinant ELAC2 protein bearing the prostate cancer-associated missense variants (Ser217Leu, Ala541Thr, Arg781His) showed no differences in enzymatic properties (Km and kcat values) compared to wild-type tRNase ZL in pre-tRNA cleavage and RNase 65 activity assays.","method":"Recombinant protein production, in vitro enzymatic assay (Km, kcat determination)","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — rigorous in vitro kinetic assay with recombinant proteins and mutagenesis, but negative result from a single lab","pmids":["15863270"],"is_preprint":false},{"year":2019,"finding":"Novel ELAC2 missense variants associated with hypertrophic cardiomyopathy impair mitochondrial RNase Z activity as demonstrated in an in vitro system. The prostate cancer-associated variant p.Arg781His also impairs mitochondrial RNase Z activity of ELAC2. Primary fibroblasts from affected individuals exhibit elevated levels of unprocessed mitochondrial RNA precursors.","method":"In vitro RNase Z activity assay with recombinant mutant proteins, structural modeling, northern blot of patient fibroblast RNA","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic activity assay with multiple disease variants plus structural modeling and patient cell confirmation; multiple orthogonal methods","pmids":["31045291"],"is_preprint":false},{"year":2004,"finding":"Drosophila RNAi knockdown of dRNaseZ (ELAC2 homolog) demonstrated it is essential for 3'-end processing of both nuclear and mitochondrial tRNAs in vivo, causing accumulation of processing intermediates with 3' extensions. Knockdown in mitotically growing imaginal discs impaired cell proliferation/viability; in endoreplicating salivary glands it reduced cell growth but not DNA replication.","method":"Heritable RNAi (GAL4/UAS system), molecular analysis of tRNA processing intermediates, tissue-specific phenotypic analysis","journal":"Insect biochemistry and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tissue-specific knockdown with direct molecular readout (tRNA processing intermediates) and defined cellular phenotypes; ortholog study, single lab","pmids":["21146608"],"is_preprint":false},{"year":2004,"finding":"The C. elegans ELAC2 homolog hoe-1 is required for germline proliferation. RNAi knockdown caused sterility due to drastic reduction in germline proliferation and cell-cycle arrest of germline nuclei. hoe-1 was required for hyperproliferation phenotypes from mutations in three different genes, and hoe-1 RNAi suppressed the multivulva phenotype from activating ras mutations (likely indirectly).","method":"RNAi knockdown, genetic epistasis analysis with germline proliferation mutants and ras gain-of-function mutants","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi with defined germline proliferation phenotype and genetic epistasis across multiple mutant backgrounds; C. elegans ortholog, single lab","pmids":["14729485"],"is_preprint":false},{"year":2024,"finding":"Cryo-EM structures of human ELAC2 in apo, pre-tRNA-bound, and tRNA-bound states revealed the structural basis for pre-tRNA binding and 3' trailer cleavage. The flexible arm domain recruits pre-tRNA; conformational rearrangement of the C-terminal helix feeds the 3' trailer into the active center for cleavage. Biochemical assays confirmed structural effects of disease-related mutations on ELAC2 activity.","method":"Cryo-EM structure determination, biochemical cleavage assays, disease-variant functional analysis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structures in multiple states plus biochemical validation of catalytic mechanism and disease mutations; multiple orthogonal methods in single rigorous study","pmids":["39494506"],"is_preprint":false},{"year":2021,"finding":"ELAC2 forms a complex with the helicase SUPV3L1 to degrade mitochondria-encoded circular RNAs (mecciRNAs). This SUPV3L1/ELAC2 degradation complex is animal-conserved and is responsible for the fast degradation of mecciRNAs in mitochondria.","method":"RNA sequencing, molecular and biochemical experiments, co-complex identification","journal":"Circulation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical complex identification with functional consequence (mecciRNA degradation); single lab, abstract does not fully detail Co-IP orthogonal validation","pmids":["39973625"],"is_preprint":false},{"year":2021,"finding":"ELAC2 is responsible for the induction of a tRNA-derived RNA fragment (tRF5-GlnCTG) from mature tRNA-Gln-CTG during respiratory syncytial virus (RSV) infection. ELAC2 is also associated with RSV N and NS1 proteins, and tRF5-GlnCTG produced via ELAC2 promotes RSV replication.","method":"Northern blot, qRT-PCR, siRNA knockdown of ELAC2, co-immunoprecipitation with RSV proteins","journal":"Frontiers in molecular biosciences","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — knockdown shows ELAC2 is required for tRF5 induction, plus Co-IP with viral proteins; single lab, novel activity not previously reported for ELAC2","pmids":["33604354"],"is_preprint":false},{"year":2021,"finding":"Expression of Drosophila RNaseZ carrying CM-linked mutations (equivalent to human ELAC2 cardiomyopathy mutations) in flies with endogenous RNaseZ knockout caused cardiac hypertrophy and reduced cardiac contractility, providing direct experimental evidence for pathogenicity of these ELAC2 variants.","method":"Transgenic Drosophila with endogenous knockout background, cardiac phenotype analysis","journal":"Disease models & mechanisms","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo loss-of-function with defined cardiac phenotype in ortholog model; single lab, Drosophila model","pmids":["34338278"],"is_preprint":false},{"year":2016,"finding":"A homozygous splicing mutation in ELAC2 (c.1423+2T>A) disrupts the canonical donor splice site of intron 15, reduces ELAC2 expression, and causes significantly increased levels of 5'-end unprocessed mt-RNAs in patient fibroblasts, confirming ELAC2's role in mt-RNA 3' processing in human disease.","method":"Whole-exome sequencing, homozygosity mapping, RT-PCR for ELAC2 expression, northern blot for unprocessed mt-RNAs in patient fibroblasts","journal":"Orphanet journal of rare diseases","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patient fibroblast molecular phenotype (accumulated unprocessed mt-RNAs) with genetic identification; single case series","pmids":["27769300"],"is_preprint":false}],"current_model":"ELAC2 encodes a zinc phosphodiesterase (tRNase ZL) that endonucleolytically cleaves the 3' trailers from mitochondrial and nuclear pre-tRNAs; cryo-EM structures reveal that its flexible arm domain recruits pre-tRNA while C-terminal helix conformational change feeds the 3' trailer into the active center; dual nuclear/mitochondrial targeting is achieved by alternative translation initiation from the first or second AUG; in mitochondria ELAC2 forms a complex with helicase SUPV3L1 to degrade mecciRNAs; ELAC2 also interacts with the gamma-tubulin complex affecting G2-M progression, and acts as a transcriptional scaffold in TGF-beta/Smad signaling by associating with activated Smad2, FAST-1, and Sp1 to potentiate p21 CDK inhibitor expression and growth arrest."},"narrative":{"mechanistic_narrative":"ELAC2 is the human tRNase Z (zinc phosphodiesterase) responsible for endonucleolytic removal of the 3' trailer from pre-tRNAs, an essential step in both nuclear and mitochondrial tRNA maturation [PMID:21593607, PMID:21146608]. Cryo-EM structures of apo, pre-tRNA-bound, and tRNA-bound enzyme establish the catalytic mechanism: a flexible arm domain recruits the pre-tRNA and a conformational rearrangement of the C-terminal helix feeds the 3' trailer into the active center for cleavage [PMID:39494506]. Dual subcellular targeting is achieved through alternative translation initiation: use of the first AUG generates a full-length, mitochondrially targeted protein, while initiation from the second AUG yields a product lacking the mitochondrial targeting sequence that is routed to the nucleus [PMID:21559454, PMID:21593607]. In mitochondria, loss-of-function mutations abolish 3'-end processing of multiple mt-tRNAs and impair mitochondrial translation, and complementation with wild-type ELAC2 restores processing, defining the enzyme as causative for infantile hypertrophic cardiomyopathy with complex I deficiency [PMID:23849775, PMID:31045291]. Beyond core tRNA processing, ELAC2 partners with the helicase SUPV3L1 to degrade mitochondria-encoded circular RNAs [PMID:39973625], and it has been linked to G2-M cell cycle progression through interaction with the gamma-tubulin complex [PMID:12569551] and to TGF-beta/Smad signaling, where it associates with activated Smad2, FAST-1, and Sp1 to potentiate p21 induction and growth arrest [PMID:16636667].","teleology":[{"year":2003,"claim":"Before ELAC2's enzymatic role was established, this work tied the protein to cell-cycle control, showing it interacts with the gamma-tubulin complex and influences G2-M progression.","evidence":"Biochemical pulldown/Co-IP and cyclin B accumulation analysis in tumor cells","pmids":["12569551"],"confidence":"Medium","gaps":["No reciprocal Co-IP or structural validation of the gamma-tubulin interaction","Mechanistic link between the interaction and G2-M delay unresolved","Relationship to the later-defined tRNase Z activity not addressed"]},{"year":2005,"claim":"Yeast and in vitro studies addressed whether catalytic residues matter and whether disease variants alter enzyme function, establishing conserved active-site requirements while finding prostate-cancer variants enzymatically silent.","evidence":"Yeast TRZ1 genetic suppression/complementation with active-site mutagenesis, plus recombinant ELAC2 kinetic (Km/kcat) assays of cancer variants","pmids":["15892892","15863270"],"confidence":"Medium","gaps":["Negative kinetic result from a single lab","Conserved histidine/P-loop requirement shown in yeast ortholog, not directly in human enzyme","Did not resolve substrate identity in human cells"]},{"year":2006,"claim":"This study extended ELAC2 beyond RNA processing into signaling, showing it scaffolds TGF-beta/Smad transcriptional output to drive growth arrest.","evidence":"Reciprocal domain-mapping Co-IP, siRNA knockdown, luciferase reporter, and growth arrest assays in prostate cells","pmids":["16636667"],"confidence":"Medium","gaps":["Single lab","Connection between nuclear scaffolding role and tRNA-processing function not integrated","In vivo relevance of p21 potentiation unknown"]},{"year":2011,"claim":"These studies defined ELAC2's core molecular function as the mitochondrial tRNA 3'-end endonuclease and explained its dual localization through alternative translation initiation.","evidence":"siRNA knockdown with RT-PCR/northern detection of mt-tRNA processing intermediates; GFP-fusion imaging with alternative start-codon mutagenesis","pmids":["21593607","21559454"],"confidence":"High","gaps":["Catalytic mechanism not yet resolved structurally","Regulation of AUG choice between compartments not characterized"]},{"year":2013,"claim":"Complementation rescue established causality between ELAC2 loss-of-function, unprocessed mt-RNA accumulation, and infantile hypertrophic cardiomyopathy with complex I deficiency.","evidence":"Patient cell/tissue RNA analysis, complementation in mutant cell lines, yeast model","pmids":["23849775"],"confidence":"High","gaps":["Why cardiac tissue is selectively vulnerable not explained","Genotype-phenotype correlations across variants not mapped"]},{"year":2016,"claim":"A patient splicing mutation reducing ELAC2 expression confirmed the human RNA-processing defect in disease and broadened the mutational spectrum.","evidence":"Whole-exome sequencing, homozygosity mapping, RT-PCR and northern blot of patient fibroblasts","pmids":["27769300"],"confidence":"Medium","gaps":["Single case series","Hypomorphic versus null contribution to phenotype not dissected"]},{"year":2019,"claim":"In vitro enzymatic testing of disease variants directly linked impaired RNase Z activity to cardiomyopathy and showed a prostate-cancer-associated variant also reduces activity.","evidence":"In vitro RNase Z activity assays with recombinant mutants, structural modeling, patient fibroblast northern blot","pmids":["31045291"],"confidence":"High","gaps":["Quantitative threshold of activity loss causing disease not defined","Reconciliation with earlier negative kinetic result for some variants not addressed"]},{"year":2021,"claim":"Three studies expanded ELAC2's RNA-related repertoire beyond canonical tRNA processing: mitochondrial mecciRNA degradation, a viral-induced tRNA fragment, and in vivo confirmation of cardiomyopathy variant pathogenicity.","evidence":"SUPV3L1/ELAC2 co-complex identification with RNA-seq; ELAC2 knockdown and viral protein Co-IP for tRF5-GlnCTG induction during RSV infection; transgenic Drosophila cardiac phenotyping","pmids":["39973625","33604354","34338278"],"confidence":"Medium","gaps":["SUPV3L1 complex lacks detailed orthogonal Co-IP validation","tRF5-GlnCTG activity is a novel ELAC2 function from a single lab","Mechanistic basis for fragment generation versus trailer cleavage unclear"]},{"year":2024,"claim":"Cryo-EM structures resolved the long-standing question of how ELAC2 engages and cleaves pre-tRNA, defining the arm-domain recruitment and C-terminal helix feeding mechanism and rationalizing disease mutations.","evidence":"Cryo-EM in apo, pre-tRNA-bound and tRNA-bound states with biochemical cleavage and disease-variant assays","pmids":["39494506"],"confidence":"High","gaps":["Structural basis for nuclear versus mitochondrial substrate specificity not addressed","Structure of the mecciRNA-degrading SUPV3L1/ELAC2 complex not determined"]},{"year":null,"claim":"How the catalytic tRNase Z core relates mechanistically to ELAC2's reported non-canonical roles in gamma-tubulin/cell-cycle control and TGF-beta/Smad transcriptional scaffolding remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural or biochemical bridge between catalytic and signaling functions","Non-canonical roles rest on single-lab studies","Whether nuclear ELAC2 acts catalytically or as a scaffold in these contexts is unclear"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,8,10,7]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,6,10]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[10,11,0]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,4]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[0,8,10]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,7,14]}],"complexes":["SUPV3L1/ELAC2 mecciRNA degradation complex"],"partners":["SUPV3L1","SMAD2","FAST-1","SP1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9BQ52","full_name":"Zinc phosphodiesterase ELAC protein 2","aliases":["ElaC homolog protein 2","Heredity prostate cancer protein 2","Ribonuclease Z 2","RNase Z 2","tRNA 3 endonuclease 2","tRNase Z 2"],"length_aa":826,"mass_kda":92.2,"function":"Zinc phosphodiesterase, which displays mitochondrial tRNA 3'-processing endonuclease activity. Involved in tRNA maturation, by removing a 3'-trailer from precursor tRNA (PubMed:21593607). Associates with mitochondrial DNA complexes at the nucleoids to initiate RNA processing and ribosome assembly (PubMed:24703694)","subcellular_location":"Mitochondrion; Mitochondrion matrix, mitochondrion nucleoid; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9BQ52/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/ELAC2","classification":"Common Essential","n_dependent_lines":1150,"n_total_lines":1208,"dependency_fraction":0.9519867549668874},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"DNAJC7","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ELAC2","total_profiled":1310},"omim":[{"mim_id":"619309","title":"PROTEIN PHOSPHATASE, MAGNESIUM/MANGANESE-DEPENDENT, 1F; PPM1F","url":"https://www.omim.org/entry/619309"},{"mim_id":"615440","title":"COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 17; COXPD17","url":"https://www.omim.org/entry/615440"},{"mim_id":"615423","title":"tRNA METHYLTRANSFERASE 10C, MITOCHONDRIAL RNAse P SUBUNIT; TRMT10C","url":"https://www.omim.org/entry/615423"},{"mim_id":"614731","title":"PROSTATE CANCER, HEREDITARY, 2; HPC2","url":"https://www.omim.org/entry/614731"},{"mim_id":"609060","title":"COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 1; COXPD1","url":"https://www.omim.org/entry/609060"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ELAC2"},"hgnc":{"alias_symbol":["FLJ10530","HPC2"],"prev_symbol":[]},"alphafold":{"accession":"Q9BQ52","domains":[{"cath_id":"3.60.15.10","chopping":"54-188_235-246_301-376_419-433","consensus_level":"medium","plddt":91.8668,"start":54,"end":433},{"cath_id":"-","chopping":"255-294","consensus_level":"high","plddt":87.7142,"start":255,"end":294},{"cath_id":"3.60.15.10","chopping":"477-773","consensus_level":"high","plddt":94.7007,"start":477,"end":773}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BQ52","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BQ52-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BQ52-F1-predicted_aligned_error_v6.png","plddt_mean":82.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ELAC2","jax_strain_url":"https://www.jax.org/strain/search?query=ELAC2"},"sequence":{"accession":"Q9BQ52","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BQ52.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BQ52/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BQ52"}},"corpus_meta":[{"pmid":"21593607","id":"PMC_21593607","title":"Involvement of human ELAC2 gene product in 3' end processing of mitochondrial tRNAs.","date":"2011","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/21593607","citation_count":168,"is_preprint":false},{"pmid":"10986046","id":"PMC_10986046","title":"Association of HPC2/ELAC2 genotypes and prostate cancer.","date":"2000","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10986046","citation_count":123,"is_preprint":false},{"pmid":"23849775","id":"PMC_23849775","title":"ELAC2 mutations cause a mitochondrial RNA processing defect associated with hypertrophic cardiomyopathy.","date":"2013","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23849775","citation_count":117,"is_preprint":false},{"pmid":"11254448","id":"PMC_11254448","title":"Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer.","date":"2001","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11254448","citation_count":85,"is_preprint":false},{"pmid":"21559454","id":"PMC_21559454","title":"Localization of human RNase Z isoforms: dual nuclear/mitochondrial targeting of the ELAC2 gene product by alternative translation initiation.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21559454","citation_count":85,"is_preprint":false},{"pmid":"11522646","id":"PMC_11522646","title":"Role of HPC2/ELAC2 in hereditary prostate cancer.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11522646","citation_count":79,"is_preprint":false},{"pmid":"11507049","id":"PMC_11507049","title":"ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11507049","citation_count":64,"is_preprint":false},{"pmid":"12569551","id":"PMC_12569551","title":"The product of the candidate prostate cancer susceptibility gene ELAC2 interacts with the gamma-tubulin complex.","date":"2003","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12569551","citation_count":61,"is_preprint":false},{"pmid":"15892892","id":"PMC_15892892","title":"Characterization of TRZ1, a yeast homolog of the human candidate prostate cancer susceptibility gene ELAC2 encoding tRNase Z.","date":"2005","source":"BMC molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15892892","citation_count":60,"is_preprint":false},{"pmid":"11431329","id":"PMC_11431329","title":"Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11431329","citation_count":51,"is_preprint":false},{"pmid":"16636667","id":"PMC_16636667","title":"ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-beta/Smad-induced growth arrest of prostate cells.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16636667","citation_count":46,"is_preprint":false},{"pmid":"12783937","id":"PMC_12783937","title":"ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer.","date":"2003","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/12783937","citation_count":46,"is_preprint":false},{"pmid":"31045291","id":"PMC_31045291","title":"Mutations in ELAC2 associated with hypertrophic cardiomyopathy impair mitochondrial tRNA 3'-end processing.","date":"2019","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/31045291","citation_count":41,"is_preprint":false},{"pmid":"20086112","id":"PMC_20086112","title":"Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men.","date":"2010","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20086112","citation_count":40,"is_preprint":false},{"pmid":"12373607","id":"PMC_12373607","title":"HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease.","date":"2002","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12373607","citation_count":34,"is_preprint":false},{"pmid":"14729485","id":"PMC_14729485","title":"The Caenorhabditis elegans homolog of the putative prostate cancer susceptibility gene ELAC2, hoe-1, plays a role in germline proliferation.","date":"2004","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/14729485","citation_count":34,"is_preprint":false},{"pmid":"20231859","id":"PMC_20231859","title":"ELAC2 polymorphisms and prostate cancer risk: a meta-analysis based on 18 case-control studies.","date":"2010","source":"Prostate cancer and prostatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/20231859","citation_count":30,"is_preprint":false},{"pmid":"15863270","id":"PMC_15863270","title":"The missense mutations in the candidate prostate cancer gene ELAC2 do not alter enzymatic properties of its product.","date":"2005","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15863270","citation_count":21,"is_preprint":false},{"pmid":"28441660","id":"PMC_28441660","title":"The Phenotype and Outcome of Infantile Cardiomyopathy Caused by a Homozygous ELAC2 Mutation.","date":"2017","source":"Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/28441660","citation_count":20,"is_preprint":false},{"pmid":"12522685","id":"PMC_12522685","title":"Association of common missense changes in ELAC2 ( HPC2) with prostate cancer in a Japanese case-control series.","date":"2002","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12522685","citation_count":20,"is_preprint":false},{"pmid":"39973625","id":"PMC_39973625","title":"Fast Degradation of MecciRNAs by SUPV3L1/ELAC2 Provides a Novel Opportunity to Tackle Heart Failure With Exogenous MecciRNA.","date":"2025","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/39973625","citation_count":19,"is_preprint":false},{"pmid":"12949798","id":"PMC_12949798","title":"Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men.","date":"2003","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12949798","citation_count":17,"is_preprint":false},{"pmid":"33604354","id":"PMC_33604354","title":"ELAC2, an Enzyme for tRNA Maturation, Plays a Role in the Cleavage of a Mature tRNA to Produce a tRNA-Derived RNA Fragment During Respiratory Syncytial Virus Infection.","date":"2021","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/33604354","citation_count":17,"is_preprint":false},{"pmid":"14695991","id":"PMC_14695991","title":"Mutational analysis of susceptibility genes RNASEL/HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer.","date":"2004","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/14695991","citation_count":17,"is_preprint":false},{"pmid":"12384782","id":"PMC_12384782","title":"ELAC2 and prostate cancer risk in Afro-Caribbeans of Tobago.","date":"2002","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12384782","citation_count":17,"is_preprint":false},{"pmid":"15593091","id":"PMC_15593091","title":"Characterization of linkage disequilibrium structure, mutation history, and tagging SNPs, and their use in association analyses: ELAC2 and familial early-onset prostate cancer.","date":"2005","source":"Genetic epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/15593091","citation_count":14,"is_preprint":false},{"pmid":"27769300","id":"PMC_27769300","title":"A homozygous splicing mutation in ELAC2 suggests phenotypic variability including intellectual disability with minimal cardiac involvement.","date":"2016","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/27769300","citation_count":13,"is_preprint":false},{"pmid":"21146608","id":"PMC_21146608","title":"RNAi knockdown of dRNaseZ, the Drosophila homolog of ELAC2, impairs growth of mitotic and endoreplicating tissues.","date":"2010","source":"Insect biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21146608","citation_count":13,"is_preprint":false},{"pmid":"15358515","id":"PMC_15358515","title":"Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2.","date":"2004","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/15358515","citation_count":12,"is_preprint":false},{"pmid":"14625808","id":"PMC_14625808","title":"HPC2/ELAC2 gene variants associated with incident prostate cancer.","date":"2003","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14625808","citation_count":12,"is_preprint":false},{"pmid":"12552947","id":"PMC_12552947","title":"Association of HPC2/ELAC2 polymorphism with prostate cancer risk in a Japanese population.","date":"2002","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12552947","citation_count":12,"is_preprint":false},{"pmid":"15368467","id":"PMC_15368467","title":"HPC2/ELAC2 polymorphism associated with Japanese sporadic prostate cancer.","date":"2004","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/15368467","citation_count":11,"is_preprint":false},{"pmid":"20819227","id":"PMC_20819227","title":"Identification and analysis of candidate fungal tRNA 3'-end processing endonucleases tRNase Zs, homologs of the putative prostate cancer susceptibility protein ELAC2.","date":"2010","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/20819227","citation_count":11,"is_preprint":false},{"pmid":"21781332","id":"PMC_21781332","title":"A survey of green plant tRNA 3'-end processing enzyme tRNase Zs, homologs of the candidate prostate cancer susceptibility protein ELAC2.","date":"2011","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/21781332","citation_count":11,"is_preprint":false},{"pmid":"34338278","id":"PMC_34338278","title":"ELAC2/RNaseZ-linked cardiac hypertrophy in Drosophila melanogaster.","date":"2021","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/34338278","citation_count":9,"is_preprint":false},{"pmid":"11751379","id":"PMC_11751379","title":"Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11751379","citation_count":9,"is_preprint":false},{"pmid":"18375959","id":"PMC_18375959","title":"Sequence variants of elaC homolog 2 (Escherichia coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study.","date":"2008","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/18375959","citation_count":8,"is_preprint":false},{"pmid":"21627373","id":"PMC_21627373","title":"Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men.","date":"2011","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/21627373","citation_count":8,"is_preprint":false},{"pmid":"39494506","id":"PMC_39494506","title":"Structural insights into human ELAC2 as a tRNA 3' processing enzyme.","date":"2024","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/39494506","citation_count":7,"is_preprint":false},{"pmid":"31452838","id":"PMC_31452838","title":"Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy.","date":"2019","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/31452838","citation_count":6,"is_preprint":false},{"pmid":"36836802","id":"PMC_36836802","title":"Novel ELAC2 Mutations in Individuals Presenting with Variably Severe Neurological Disease in the Presence or Absence of Cardiomyopathy.","date":"2023","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36836802","citation_count":6,"is_preprint":false},{"pmid":"31321101","id":"PMC_31321101","title":"Prevalence of the Ser217Leu Variant of the ELAC2 Gene and Its Association with Prostate Cancer in Population of the Littoral Region of Cameroon.","date":"2019","source":"Prostate cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31321101","citation_count":4,"is_preprint":false},{"pmid":"36831280","id":"PMC_36831280","title":"ELAC2 Functions as a Key Gene in the Early Development of Placental Formation Based on WGCNA.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36831280","citation_count":3,"is_preprint":false},{"pmid":"36643816","id":"PMC_36643816","title":"Carriage of Ser217Leu and Ala541Thr Variants of ELAC2 Gene and Risk Factors in Patients with Prostate Cancer in Burkina Faso.","date":"2022","source":"Prostate cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36643816","citation_count":2,"is_preprint":false},{"pmid":"24052700","id":"PMC_24052700","title":"Polymorphisms of HPC2/ELAC2 and SRD5A2 (5α-Reductase Type II) Genes in Prostate Cancer.","date":"2011","source":"Balkan journal of medical genetics : BJMG","url":"https://pubmed.ncbi.nlm.nih.gov/24052700","citation_count":2,"is_preprint":false},{"pmid":"37353407","id":"PMC_37353407","title":"ELAC2 is a functional prostate cancer risk allele.","date":"2023","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37353407","citation_count":2,"is_preprint":false},{"pmid":"35946480","id":"PMC_35946480","title":"Pseudohypoaldosteronism associated with hypertrophic cardiomyopathy, hypertension and thrombocytosis due to mutation in the ELAC2 gene: a case report.","date":"2022","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/35946480","citation_count":1,"is_preprint":false},{"pmid":"37329658","id":"PMC_37329658","title":"Microcystin-leucine-arginine promotes the development of gallbladder carcinoma via regulating ELAC2.","date":"2023","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/37329658","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.05.15.25327006","title":"High prevalence of deleterious germline variants in cancer risk genes among subjects with young-onset, sporadic pituitary macroadenomas","date":"2025-05-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.15.25327006","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":25561,"output_tokens":3840,"usd":0.067142,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11680,"output_tokens":3405,"usd":0.071763,"stage2_stop_reason":"end_turn"},"total_usd":0.138905,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"ELAC2 functions as tRNase Z in human mitochondria, responsible for 3' end processing of mitochondrial tRNAs. Silencing ELAC2 by siRNA resulted in impaired 3' end processing of multiple mt-tRNAs (tRNA-Val, tRNA-Lys, tRNA-Arg, tRNA-Gly, tRNA-Leu(UUR), tRNA-Glu) encoded on both mtDNA strands, establishing its role as the mitochondrial 3'-end endonuclease.\",\n      \"method\": \"siRNA knockdown, RT-PCR, northern blot analysis\",\n      \"journal\": \"RNA biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean knockdown with defined molecular phenotype (tRNA processing intermediates), replicated across multiple mt-tRNA substrates, corroborated by independent studies\",\n      \"pmids\": [\"21593607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ELAC2 exhibits dual nuclear/mitochondrial localization. Alternative translation initiation from the second AUG of ELAC2 mRNA (due to unfavorable context of the first AUG) produces a protein lacking the mitochondrial targeting sequence, which is routed to the nucleus instead. The full-length protein (translation from the first AUG) localizes to mitochondria.\",\n      \"method\": \"GFP fusion protein expression, fluorescence microscopy, immunofluorescence, alternative start codon mutagenesis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct localization by GFP fusion imaging combined with mechanistic explanation via alternative translation initiation mutagenesis; corroborated by immunofluorescence in a separate study (PMID:21593607)\",\n      \"pmids\": [\"21559454\", \"21593607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Mutations in ELAC2 cause accumulation of mitochondrial RNA precursors (unprocessed mt-tRNA 3' ends) and impaired mitochondrial translation, leading to infantile hypertrophic cardiomyopathy and complex I deficiency. Complementation of mutant cell lines with wild-type ELAC2 restored RNA processing, establishing causality.\",\n      \"method\": \"Patient cell/tissue RNA analysis, complementation experiments in mutant cell lines, yeast model\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — complementation rescue experiment directly linking ELAC2 loss-of-function to mt-RNA processing defect, replicated in muscle, fibroblasts, and yeast model\",\n      \"pmids\": [\"23849775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ELAC2 physically interacts with the gamma-tubulin complex. Overexpression of ELAC2 in tumor cells causes a delay in G2-M progression with accumulation of cyclin B levels.\",\n      \"method\": \"Biochemical pulldown/co-immunoprecipitation, cell cycle analysis (cyclin B accumulation)\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, interaction reported by biochemical analysis without reciprocal Co-IP or structural validation; functional link to G2-M delay observed but mechanism not fully resolved\",\n      \"pmids\": [\"12569551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ELAC2 associates with activated Smad2 via an interaction between the C-terminal MH2 domain of Smad2 and the N-terminal region of ELAC2. ELAC2 also associates with the nuclear Smad2 partner FAST-1 and potentiates the interaction of activated Smad2 with transcription factor Sp1. siRNA-mediated knockdown of ELAC2 suppresses TGF-beta-induced growth arrest in prostate cells, and ELAC2 potentiates activation of the p21 CDK inhibitor promoter by TGF-beta.\",\n      \"method\": \"Co-immunoprecipitation, domain mapping, siRNA knockdown, luciferase reporter assay, growth arrest assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal domain-mapping Co-IP plus functional siRNA knockdown with defined growth arrest phenotype and reporter assay; single lab\",\n      \"pmids\": [\"16636667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The yeast ELAC2 homolog TRZ1 is involved in RNA processing in vivo. A trz1 deletion mutant's temperature sensitivity is rescued by multiple copies of REX2 (encoding an RNA 3' processing protein). The conserved histidine motif and C-terminal P-loop nucleotide-binding motif of Trz1p are essential for function, as mutations in these motifs abolish complementation.\",\n      \"method\": \"Yeast genetic suppression screen, plasmid-based complementation, site-directed mutagenesis\",\n      \"journal\": \"BMC molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (suppression by REX2) plus active-site mutagenesis demonstrating catalytic residue requirements; yeast model, single lab\",\n      \"pmids\": [\"15892892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Recombinant ELAC2 protein bearing the prostate cancer-associated missense variants (Ser217Leu, Ala541Thr, Arg781His) showed no differences in enzymatic properties (Km and kcat values) compared to wild-type tRNase ZL in pre-tRNA cleavage and RNase 65 activity assays.\",\n      \"method\": \"Recombinant protein production, in vitro enzymatic assay (Km, kcat determination)\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — rigorous in vitro kinetic assay with recombinant proteins and mutagenesis, but negative result from a single lab\",\n      \"pmids\": [\"15863270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Novel ELAC2 missense variants associated with hypertrophic cardiomyopathy impair mitochondrial RNase Z activity as demonstrated in an in vitro system. The prostate cancer-associated variant p.Arg781His also impairs mitochondrial RNase Z activity of ELAC2. Primary fibroblasts from affected individuals exhibit elevated levels of unprocessed mitochondrial RNA precursors.\",\n      \"method\": \"In vitro RNase Z activity assay with recombinant mutant proteins, structural modeling, northern blot of patient fibroblast RNA\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic activity assay with multiple disease variants plus structural modeling and patient cell confirmation; multiple orthogonal methods\",\n      \"pmids\": [\"31045291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Drosophila RNAi knockdown of dRNaseZ (ELAC2 homolog) demonstrated it is essential for 3'-end processing of both nuclear and mitochondrial tRNAs in vivo, causing accumulation of processing intermediates with 3' extensions. Knockdown in mitotically growing imaginal discs impaired cell proliferation/viability; in endoreplicating salivary glands it reduced cell growth but not DNA replication.\",\n      \"method\": \"Heritable RNAi (GAL4/UAS system), molecular analysis of tRNA processing intermediates, tissue-specific phenotypic analysis\",\n      \"journal\": \"Insect biochemistry and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific knockdown with direct molecular readout (tRNA processing intermediates) and defined cellular phenotypes; ortholog study, single lab\",\n      \"pmids\": [\"21146608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The C. elegans ELAC2 homolog hoe-1 is required for germline proliferation. RNAi knockdown caused sterility due to drastic reduction in germline proliferation and cell-cycle arrest of germline nuclei. hoe-1 was required for hyperproliferation phenotypes from mutations in three different genes, and hoe-1 RNAi suppressed the multivulva phenotype from activating ras mutations (likely indirectly).\",\n      \"method\": \"RNAi knockdown, genetic epistasis analysis with germline proliferation mutants and ras gain-of-function mutants\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi with defined germline proliferation phenotype and genetic epistasis across multiple mutant backgrounds; C. elegans ortholog, single lab\",\n      \"pmids\": [\"14729485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structures of human ELAC2 in apo, pre-tRNA-bound, and tRNA-bound states revealed the structural basis for pre-tRNA binding and 3' trailer cleavage. The flexible arm domain recruits pre-tRNA; conformational rearrangement of the C-terminal helix feeds the 3' trailer into the active center for cleavage. Biochemical assays confirmed structural effects of disease-related mutations on ELAC2 activity.\",\n      \"method\": \"Cryo-EM structure determination, biochemical cleavage assays, disease-variant functional analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structures in multiple states plus biochemical validation of catalytic mechanism and disease mutations; multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"39494506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ELAC2 forms a complex with the helicase SUPV3L1 to degrade mitochondria-encoded circular RNAs (mecciRNAs). This SUPV3L1/ELAC2 degradation complex is animal-conserved and is responsible for the fast degradation of mecciRNAs in mitochondria.\",\n      \"method\": \"RNA sequencing, molecular and biochemical experiments, co-complex identification\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical complex identification with functional consequence (mecciRNA degradation); single lab, abstract does not fully detail Co-IP orthogonal validation\",\n      \"pmids\": [\"39973625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ELAC2 is responsible for the induction of a tRNA-derived RNA fragment (tRF5-GlnCTG) from mature tRNA-Gln-CTG during respiratory syncytial virus (RSV) infection. ELAC2 is also associated with RSV N and NS1 proteins, and tRF5-GlnCTG produced via ELAC2 promotes RSV replication.\",\n      \"method\": \"Northern blot, qRT-PCR, siRNA knockdown of ELAC2, co-immunoprecipitation with RSV proteins\",\n      \"journal\": \"Frontiers in molecular biosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — knockdown shows ELAC2 is required for tRF5 induction, plus Co-IP with viral proteins; single lab, novel activity not previously reported for ELAC2\",\n      \"pmids\": [\"33604354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Expression of Drosophila RNaseZ carrying CM-linked mutations (equivalent to human ELAC2 cardiomyopathy mutations) in flies with endogenous RNaseZ knockout caused cardiac hypertrophy and reduced cardiac contractility, providing direct experimental evidence for pathogenicity of these ELAC2 variants.\",\n      \"method\": \"Transgenic Drosophila with endogenous knockout background, cardiac phenotype analysis\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo loss-of-function with defined cardiac phenotype in ortholog model; single lab, Drosophila model\",\n      \"pmids\": [\"34338278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A homozygous splicing mutation in ELAC2 (c.1423+2T>A) disrupts the canonical donor splice site of intron 15, reduces ELAC2 expression, and causes significantly increased levels of 5'-end unprocessed mt-RNAs in patient fibroblasts, confirming ELAC2's role in mt-RNA 3' processing in human disease.\",\n      \"method\": \"Whole-exome sequencing, homozygosity mapping, RT-PCR for ELAC2 expression, northern blot for unprocessed mt-RNAs in patient fibroblasts\",\n      \"journal\": \"Orphanet journal of rare diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient fibroblast molecular phenotype (accumulated unprocessed mt-RNAs) with genetic identification; single case series\",\n      \"pmids\": [\"27769300\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ELAC2 encodes a zinc phosphodiesterase (tRNase ZL) that endonucleolytically cleaves the 3' trailers from mitochondrial and nuclear pre-tRNAs; cryo-EM structures reveal that its flexible arm domain recruits pre-tRNA while C-terminal helix conformational change feeds the 3' trailer into the active center; dual nuclear/mitochondrial targeting is achieved by alternative translation initiation from the first or second AUG; in mitochondria ELAC2 forms a complex with helicase SUPV3L1 to degrade mecciRNAs; ELAC2 also interacts with the gamma-tubulin complex affecting G2-M progression, and acts as a transcriptional scaffold in TGF-beta/Smad signaling by associating with activated Smad2, FAST-1, and Sp1 to potentiate p21 CDK inhibitor expression and growth arrest.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ELAC2 is the human tRNase Z (zinc phosphodiesterase) responsible for endonucleolytic removal of the 3' trailer from pre-tRNAs, an essential step in both nuclear and mitochondrial tRNA maturation [#0, #8]. Cryo-EM structures of apo, pre-tRNA-bound, and tRNA-bound enzyme establish the catalytic mechanism: a flexible arm domain recruits the pre-tRNA and a conformational rearrangement of the C-terminal helix feeds the 3' trailer into the active center for cleavage [#10]. Dual subcellular targeting is achieved through alternative translation initiation: use of the first AUG generates a full-length, mitochondrially targeted protein, while initiation from the second AUG yields a product lacking the mitochondrial targeting sequence that is routed to the nucleus [#1]. In mitochondria, loss-of-function mutations abolish 3'-end processing of multiple mt-tRNAs and impair mitochondrial translation, and complementation with wild-type ELAC2 restores processing, defining the enzyme as causative for infantile hypertrophic cardiomyopathy with complex I deficiency [#2, #7]. Beyond core tRNA processing, ELAC2 partners with the helicase SUPV3L1 to degrade mitochondria-encoded circular RNAs [#11], and it has been linked to G2-M cell cycle progression through interaction with the gamma-tubulin complex [#3] and to TGF-beta/Smad signaling, where it associates with activated Smad2, FAST-1, and Sp1 to potentiate p21 induction and growth arrest [#4].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Before ELAC2's enzymatic role was established, this work tied the protein to cell-cycle control, showing it interacts with the gamma-tubulin complex and influences G2-M progression.\",\n      \"evidence\": \"Biochemical pulldown/Co-IP and cyclin B accumulation analysis in tumor cells\",\n      \"pmids\": [\"12569551\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No reciprocal Co-IP or structural validation of the gamma-tubulin interaction\", \"Mechanistic link between the interaction and G2-M delay unresolved\", \"Relationship to the later-defined tRNase Z activity not addressed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Yeast and in vitro studies addressed whether catalytic residues matter and whether disease variants alter enzyme function, establishing conserved active-site requirements while finding prostate-cancer variants enzymatically silent.\",\n      \"evidence\": \"Yeast TRZ1 genetic suppression/complementation with active-site mutagenesis, plus recombinant ELAC2 kinetic (Km/kcat) assays of cancer variants\",\n      \"pmids\": [\"15892892\", \"15863270\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Negative kinetic result from a single lab\", \"Conserved histidine/P-loop requirement shown in yeast ortholog, not directly in human enzyme\", \"Did not resolve substrate identity in human cells\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"This study extended ELAC2 beyond RNA processing into signaling, showing it scaffolds TGF-beta/Smad transcriptional output to drive growth arrest.\",\n      \"evidence\": \"Reciprocal domain-mapping Co-IP, siRNA knockdown, luciferase reporter, and growth arrest assays in prostate cells\",\n      \"pmids\": [\"16636667\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Connection between nuclear scaffolding role and tRNA-processing function not integrated\", \"In vivo relevance of p21 potentiation unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"These studies defined ELAC2's core molecular function as the mitochondrial tRNA 3'-end endonuclease and explained its dual localization through alternative translation initiation.\",\n      \"evidence\": \"siRNA knockdown with RT-PCR/northern detection of mt-tRNA processing intermediates; GFP-fusion imaging with alternative start-codon mutagenesis\",\n      \"pmids\": [\"21593607\", \"21559454\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic mechanism not yet resolved structurally\", \"Regulation of AUG choice between compartments not characterized\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Complementation rescue established causality between ELAC2 loss-of-function, unprocessed mt-RNA accumulation, and infantile hypertrophic cardiomyopathy with complex I deficiency.\",\n      \"evidence\": \"Patient cell/tissue RNA analysis, complementation in mutant cell lines, yeast model\",\n      \"pmids\": [\"23849775\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why cardiac tissue is selectively vulnerable not explained\", \"Genotype-phenotype correlations across variants not mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"A patient splicing mutation reducing ELAC2 expression confirmed the human RNA-processing defect in disease and broadened the mutational spectrum.\",\n      \"evidence\": \"Whole-exome sequencing, homozygosity mapping, RT-PCR and northern blot of patient fibroblasts\",\n      \"pmids\": [\"27769300\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single case series\", \"Hypomorphic versus null contribution to phenotype not dissected\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"In vitro enzymatic testing of disease variants directly linked impaired RNase Z activity to cardiomyopathy and showed a prostate-cancer-associated variant also reduces activity.\",\n      \"evidence\": \"In vitro RNase Z activity assays with recombinant mutants, structural modeling, patient fibroblast northern blot\",\n      \"pmids\": [\"31045291\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative threshold of activity loss causing disease not defined\", \"Reconciliation with earlier negative kinetic result for some variants not addressed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Three studies expanded ELAC2's RNA-related repertoire beyond canonical tRNA processing: mitochondrial mecciRNA degradation, a viral-induced tRNA fragment, and in vivo confirmation of cardiomyopathy variant pathogenicity.\",\n      \"evidence\": \"SUPV3L1/ELAC2 co-complex identification with RNA-seq; ELAC2 knockdown and viral protein Co-IP for tRF5-GlnCTG induction during RSV infection; transgenic Drosophila cardiac phenotyping\",\n      \"pmids\": [\"39973625\", \"33604354\", \"34338278\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"SUPV3L1 complex lacks detailed orthogonal Co-IP validation\", \"tRF5-GlnCTG activity is a novel ELAC2 function from a single lab\", \"Mechanistic basis for fragment generation versus trailer cleavage unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Cryo-EM structures resolved the long-standing question of how ELAC2 engages and cleaves pre-tRNA, defining the arm-domain recruitment and C-terminal helix feeding mechanism and rationalizing disease mutations.\",\n      \"evidence\": \"Cryo-EM in apo, pre-tRNA-bound and tRNA-bound states with biochemical cleavage and disease-variant assays\",\n      \"pmids\": [\"39494506\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for nuclear versus mitochondrial substrate specificity not addressed\", \"Structure of the mecciRNA-degrading SUPV3L1/ELAC2 complex not determined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the catalytic tRNase Z core relates mechanistically to ELAC2's reported non-canonical roles in gamma-tubulin/cell-cycle control and TGF-beta/Smad transcriptional scaffolding remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural or biochemical bridge between catalytic and signaling functions\", \"Non-canonical roles rest on single-lab studies\", \"Whether nuclear ELAC2 acts catalytically or as a scaffold in these contexts is unclear\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 8, 10, 7]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 6, 10]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [10, 11, 0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [0, 8, 10]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 7, 14]}\n    ],\n    \"complexes\": [\"SUPV3L1/ELAC2 mecciRNA degradation complex\"],\n    \"partners\": [\"SUPV3L1\", \"SMAD2\", \"FAST-1\", \"SP1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}